J. Goldman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

J. Goldman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,368	Closed	-$1.15M	–	652
2025 Q4	$1.34M	Buy	+3,368	New	+$1.49M	0.04%	355
2025 Q2	–	Sell	-74,185	Closed	-$20M	–	452
2025 Q1	$20M	Buy	+74,185	New	+$19.1M	0.49%	57

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's ALNY Position: Q1 2026 in Review

J. Goldman & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,368 shares — an estimated $1.15M sold.

J. Goldman & Co first reported a position in ALNY in Q1 2025 and held it in 2 quarters. The position peaked at $20M in Q1 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

J. Goldman & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
J. Goldman & Co sold 3,368 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
J. Goldman & Co first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 2 quarters.
J. Goldman & Co's Alnylam Pharmaceuticals position peaked at $20M in Q1 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.